Anakinra treatment in patients with acute Kawasaki disease with coronary artery aneurysms: A Phase I/IIa trial

To determine the safety, pharmacokinetics, and immunomodulatory effects of two- to six-weeks of anakinra in patients with acute KD Kawasaki disease with coronary artery aneurysms (CAA).

source https://www.jpeds.com/article/S0022-3476(21)01242-7/fulltext?rss=yes

Comments

Popular posts from this blog

Out Of The Old Black Bag

Medical School in The Fall